Distribution of events in 312 Philadelphia-negative ALL patients according to HR criteria, in hierarchical order
| . | HR criteria (in hierarchical order) . | . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (1) MRD-HR . | (2) Resistant IA . | (3) t(4;11) . | (4) PPR . | (5) Total . | ||||||
| n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | |
| Total | 132 | 42.3 | 17 | 5.4 | 11 | 3.5 | 152 | 48.7 | 312 | |
| Death in induction | 0 | 0 | 0 | 1 | 0.7 | 1 | 0.3 | |||
| Resistant to protocol | 3 | 2.3 | 3 | 17.6 | 0 | 0 | 6 | 1.9 | ||
| Relapses (deaths) | 56 (46) | 42.4 | 6 (6) | 35.3 | 5 (4) | 45.4 | 38 (20) | 25.0 | 105 (76) | 33.7 |
| Timing | ||||||||||
| <6 mo | 7 | 5.3 | 0 | 0 | 1 | 0.7 | 8 | 2.5 | ||
| 6-18 mo | 22 | 16.6 | 2 | 11.8 | 5 | 45.4 | 14 | 9.2 | 43 | 13.8 |
| 18-30 mo | 19 | 14.4 | 3 | 17.6 | 0 | 12 | 7.9 | 34 | 10.9 | |
| ≥30 mo | 8 | 6.1 | 1 | 5.9 | 0 | 11 | 7.2 | 20 | 6.5 | |
| Site | ||||||||||
| BM | 37 | 28.0 | 4 | 23.5 | 4 | 36.3 | 22 | 14.5 | 67 | 21.5 |
| CNS | 5 | 3.8 | 0 | 0 | 4 | 2.6 | 9 | 2.9 | ||
| Testis | 3 | 2.3 | 0 | 1 | 9.1 | 1 | 0.7 | 5 | 1.6 | |
| BM + others | 8 | 6.0 | 1 | 5.9 | 0 | 7 | 4.6 | 16 | 5.1 | |
| Others | 3 | 2.3 | 1 | 5.9 | 0 | 4 | 2.6 | 8 | 2.6 | |
| Second malignant neoplasm | 5* | 3.8 | 0 | 0 | 3† | 2.0 | 8 | 2.6 | ||
| Death in CCR | 10 | 7.6 | 1 | 5.9 | 2 | 18.2 | 2 | 1.3 | 15 | 4.8 |
| After chemotherapy‡ | 2 | 1.5 | 1 | 5.9 | 1 | 9.1 | 2 | 1.3 | 6 | 1.9 |
| After HSCT | 8 | 6.1 | 0 | 1 | 9.1 | 0 | 9 | 2.9 | ||
| CCR | 58 | 43.9 | 7 | 41.2 | 4 | 36.4 | 108 | 71.0 | 177 | 56.7 |
| 5-y EFS (SE) | 45.9% (4.4) | 41.2% (11.9) | 36.4% (14.5) | 74.0% (3.6) | 58.9% (2.8) | |||||
| 10-y EFS (SE) | 42.9% (4.4) | 41.2% (11.9) | 36.4% (14.5) | 68.8% (4.1) | 55.2% (3.0) | |||||
| P < .001 | ||||||||||
| 5-y survival (SE) | 54.1% (4.4) | 41.2% (11.9) | 45.5% (15.0) | 86.7% (2.8) | 68.9% (2.6) | |||||
| 10-y survival (SE) | 52.5% (4.4) | 41.2% (11.9) | 45.5% (15.0) | 83.8% (3.0) | 66.8% (2.7) | |||||
| P < .001 | ||||||||||
| . | HR criteria (in hierarchical order) . | . | . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (1) MRD-HR . | (2) Resistant IA . | (3) t(4;11) . | (4) PPR . | (5) Total . | ||||||
| n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | |
| Total | 132 | 42.3 | 17 | 5.4 | 11 | 3.5 | 152 | 48.7 | 312 | |
| Death in induction | 0 | 0 | 0 | 1 | 0.7 | 1 | 0.3 | |||
| Resistant to protocol | 3 | 2.3 | 3 | 17.6 | 0 | 0 | 6 | 1.9 | ||
| Relapses (deaths) | 56 (46) | 42.4 | 6 (6) | 35.3 | 5 (4) | 45.4 | 38 (20) | 25.0 | 105 (76) | 33.7 |
| Timing | ||||||||||
| <6 mo | 7 | 5.3 | 0 | 0 | 1 | 0.7 | 8 | 2.5 | ||
| 6-18 mo | 22 | 16.6 | 2 | 11.8 | 5 | 45.4 | 14 | 9.2 | 43 | 13.8 |
| 18-30 mo | 19 | 14.4 | 3 | 17.6 | 0 | 12 | 7.9 | 34 | 10.9 | |
| ≥30 mo | 8 | 6.1 | 1 | 5.9 | 0 | 11 | 7.2 | 20 | 6.5 | |
| Site | ||||||||||
| BM | 37 | 28.0 | 4 | 23.5 | 4 | 36.3 | 22 | 14.5 | 67 | 21.5 |
| CNS | 5 | 3.8 | 0 | 0 | 4 | 2.6 | 9 | 2.9 | ||
| Testis | 3 | 2.3 | 0 | 1 | 9.1 | 1 | 0.7 | 5 | 1.6 | |
| BM + others | 8 | 6.0 | 1 | 5.9 | 0 | 7 | 4.6 | 16 | 5.1 | |
| Others | 3 | 2.3 | 1 | 5.9 | 0 | 4 | 2.6 | 8 | 2.6 | |
| Second malignant neoplasm | 5* | 3.8 | 0 | 0 | 3† | 2.0 | 8 | 2.6 | ||
| Death in CCR | 10 | 7.6 | 1 | 5.9 | 2 | 18.2 | 2 | 1.3 | 15 | 4.8 |
| After chemotherapy‡ | 2 | 1.5 | 1 | 5.9 | 1 | 9.1 | 2 | 1.3 | 6 | 1.9 |
| After HSCT | 8 | 6.1 | 0 | 1 | 9.1 | 0 | 9 | 2.9 | ||
| CCR | 58 | 43.9 | 7 | 41.2 | 4 | 36.4 | 108 | 71.0 | 177 | 56.7 |
| 5-y EFS (SE) | 45.9% (4.4) | 41.2% (11.9) | 36.4% (14.5) | 74.0% (3.6) | 58.9% (2.8) | |||||
| 10-y EFS (SE) | 42.9% (4.4) | 41.2% (11.9) | 36.4% (14.5) | 68.8% (4.1) | 55.2% (3.0) | |||||
| P < .001 | ||||||||||
| 5-y survival (SE) | 54.1% (4.4) | 41.2% (11.9) | 45.5% (15.0) | 86.7% (2.8) | 68.9% (2.6) | |||||
| 10-y survival (SE) | 52.5% (4.4) | 41.2% (11.9) | 45.5% (15.0) | 83.8% (3.0) | 66.8% (2.7) | |||||
| P < .001 | ||||||||||
Two AML (0.6, 2.7 y from diagnosis), 1 MDS (1.6), 1 Ewing sarcoma (3.7), and 1 malignant reticuloendotheliosis (1.2).
Two glioblastomas (4.2 and 4.8 y from diagnosis) and 1 AML (1.7).
Cause of death and time of death were hemolytic uremic syndrome (n = 1, at 0.5 y from diagnosis), sepsis (n = 2, at 0.2 and 0.3 y), pneumonia (n = 2, at 0.5 and 1.3 y), and brain hemorrhage (n = 1, at 1.0 y).